DOI QR코드

DOI QR Code

MicroRNA-155 Expression has Prognostic Value in Patients with Non-small Cell Lung Cancer and Digestive System Carcinomas

  • Xu, Tong-Peng (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) ;
  • Zhu, Can-Hong (Department of Gerontology, Affiliated People's Hospital of Jiangsu University) ;
  • Zhang, Jian (Department of General Surgery, Huai'an First People's Hospital, Nanjing Medical University) ;
  • Xia, Rui (Department of Biochemistry and Molecular Biology, Nanjing Medical University) ;
  • Wu, Feng-Lei (Department of Oncology, First People Hospital of Lianyungang, Lianyungang, Jiangsu Province) ;
  • Han, Liang (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) ;
  • Shen, Hua (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) ;
  • Liu, Ling-Xiang (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University) ;
  • Shu, Yong-Qian (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University)
  • Published : 2013.12.31

Abstract

Objective: Published data have shown that microRNAs (miRNAs) could play a potential role as diagnostic and prognostic indicators in cancers. Data for the predictive value of microRNA-155 are inconclusive. The aim of the present analysis was therefore to evaluate the role of miR-155 in prognosis for patients with a variety of carcinomas. Methods: Relevant studies were identified by searching PubMed and EMBASE. Data were extracted from studies comparing overall survival (OS), recurrence-free survival (RFS) or cancer-specific survival (CSS) in patients with carcinoma with higher miR-155 expression and those with lower levels. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of miR-155 for clinical outcome were calculated. Results: A total of 15 studies were included. The pooled hazard ratio (HR) for OS of higher miR-155 expression in cancerous tissue was 1.89 (95% CI: 1.20-2.99, P=0.006), which could markedly predict poorer survival in general cancer. For RFS/CSS, elevated miR-155 was also associated with poor prognosis of cancer (HR=1.50, 95% CI: 1.10-2.05, P=0.01). On subgroup analysis, the pooled HR for OS in non-small cell lung cancer (NSCLC) was 2.09 (95% CI: 0.68-6.41, P > 0.05), but for RFS/CSS was 1.28 (95% CI: 1.05-1.55, P=0.015), with statistical significance; the pooled HRs for OS and RFS/CSS in digestive system neoplasms were 3.04 (95% CI: 1.48-6.24, P=0.003) and 2.61 (95% CI: 1.98-3.42, P<0.05), respectively. Conclusions: The results indicated that the miR-155 expression level plays a prognostic role in patients with cancer, especially NSCLCs and digestive system carcinomas.

References

  1. Ambros V (2003). MicroRNAs pathways in flies and worms: growth, death, fat, stress, and timing. Cell, 113, 673-6. https://doi.org/10.1016/S0092-8674(03)00428-8
  2. Calin GA, Croce CM (2006). MicroRNA-cancer connection: the beginning of a new tale. Cancer Res, 66, 7390-4. https://doi.org/10.1158/0008-5472.CAN-06-0800
  3. Chen CZ (2005). MicroRNAs as oncogenes and tumor suppressors. N Engl J Med, 353, 1768-71. https://doi.org/10.1056/NEJMp058190
  4. Chen J, Wang BC, Tang JH (2012). Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol, 106, 260-6. https://doi.org/10.1002/jso.22153
  5. Donnem T, Eklo K, Berg T, et al (2011). Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med, 9, 6. https://doi.org/10.1186/1479-5876-9-6
  6. Du ZM, Hu LF, Wang HY, et al (2011). Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic Marker JMJD1A. PLoS One, 6, e19137. https://doi.org/10.1371/journal.pone.0019137
  7. Esquela-Kerscher A, Slack FJ (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69. https://doi.org/10.1038/nrc1840
  8. Gironella M, Seux M, Xie MJ, et al (2007). Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155 and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA, 104, 16170-5. https://doi.org/10.1073/pnas.0703942104
  9. Greither T, Grochola LF, Udelnow A, et al (2010). Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer, 126, 73-80. https://doi.org/10.1002/ijc.24687
  10. Han ZB, Chen HY, Fan JW, et al (2012). Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol, 138, 153-61. https://doi.org/10.1007/s00432-011-1076-z
  11. Hayes DF, Isaacs C, Stearns V (2000). Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia, 6, 375-92.
  12. Huang YH, Lin KH, Chen HC, et al (2012). Identification of postoperative prognostic MicroRNA predictors in hepatocellular carcinoma. PLoS One, 7, e37188. https://doi.org/10.1371/journal.pone.0037188
  13. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70. https://doi.org/10.1158/0008-5472.CAN-05-1783
  14. Ishihara K, Sasaki D, Tsuruda K, et al (2012). Impact of miR- 155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol, 36, 560-5. https://doi.org/10.1016/j.canep.2012.07.002
  15. Jiang S, Zhang HW, Lu MH, et al (2010). MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res, 70, 3119-27. https://doi.org/10.1158/0008-5472.CAN-09-4250
  16. Jung I, Aguiar RC (2009). MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma. Br J Haematol, 144, 138-40. https://doi.org/10.1111/j.1365-2141.2008.07424.x
  17. Kong W, Yang H, He L, et al (2008). MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol, 28, 6773-84. https://doi.org/10.1128/MCB.00941-08
  18. Lee EJ, Gusev Y, Jiang J, et al (2007). Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer, 120, 1046-54.
  19. Lee RC, Feinbaum RL, Ambros V, et al (1993). Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843-54. https://doi.org/10.1016/0092-8674(93)90529-Y
  20. Monsalvez V, Montes-Moreno S, Artiga MJ, et al (2013). MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Mod Pathol, 26, 171-81. https://doi.org/10.1038/modpathol.2012.149
  21. Nana-Sinkam P, Croce CM (2010). MicroRNAs in diagnosis and prognosis in cancer: what does the future hold? Pharmacogenomics, 11, 667-9. https://doi.org/10.2217/pgs.10.57
  22. Nikiforova MN, Tseng GC, Steward D, et al (2008). MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab, 93, 1600-8. https://doi.org/10.1210/jc.2007-2696
  23. O'Connell RM, Rao DS, Chaudhuri AA, et al (2008). Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med, 205, 585-594. https://doi.org/10.1084/jem.20072108
  24. Ovcharenko D, Kelnar K, Johnson C, et al (2007). Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL- induced apoptosis pathway. Cancer Res, 67, 10782-8. https://doi.org/10.1158/0008-5472.CAN-07-1484
  25. Papaconstantinou IG, Manta A, Gazouli M, et al (2013). Expression of MicroRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas, 42, 67-71. https://doi.org/10.1097/MPA.0b013e3182592ba7
  26. Raponi M, Dossey L, Jatkoe T, et al (2009). MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res, 69, 5776-83. https://doi.org/10.1158/0008-5472.CAN-09-0587
  27. Saito M, Schetter AJ, Mollerup S, et al (2011). The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res, 17, 1875-82. https://doi.org/10.1158/1078-0432.CCR-10-2961
  28. Shibuya H, Iinuma H, Shimada R, et al (2010). Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology, 79, 313-20. https://doi.org/10.1159/000323283
  29. Shinmei S, Sakamoto N, Goto K, et al (2013). MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma. Int J Urol, 20, 468-77. https://doi.org/10.1111/j.1442-2042.2012.03182.x
  30. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol, 25, 603-5. https://doi.org/10.1007/s10654-010-9491-z
  31. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA, 283, 2008-12. https://doi.org/10.1001/jama.283.15.2008
  32. Szafranska AE, Davison TS, John J, et al (2007). MicroRNA expression alterations are linked to tumorigenesis and nonneoplastic processes in pancreatic ductal adenocarcinoma. Oncogene, 26, 4442-52. https://doi.org/10.1038/sj.onc.1210228
  33. Thompson RC, Herscovitch M, Zhao I, et al (2011). NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem, 286, 1675-82. https://doi.org/10.1074/jbc.M110.177063
  34. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  35. Voortman J, Goto A, Mendiboure J, et al (2010). MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res, 70, 8288-98. https://doi.org/10.1158/0008-5472.CAN-10-1348
  36. Wang QZ, Xu W, Habib N, et al (2009). Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets, 9, 572-94. https://doi.org/10.2174/156800909788486731
  37. Wang X, Tang S, Le SY, et al (2008). Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 3, e2557. https://doi.org/10.1371/journal.pone.0002557
  38. Yamanaka Y, Tagawa H, Takahashi N, et al (2009). Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood, 114, 3265-75. https://doi.org/10.1182/blood-2009-06-222794
  39. Yanaihara N, Caplen N, Bowman E, et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-98. https://doi.org/10.1016/j.ccr.2006.01.025

Cited by

  1. MicroRNAs as Promising Biomarkers for Tumor-staging: Evaluation of MiR21 MiR155 MiR29a and MiR92a in Predicting Tumor Stage of Rectal Cancer vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5175
  2. Bevacizumab Concomitant with Chemotherapy is Effective in Treating Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5945
  3. miR-421, miR-155 and miR-650: Emerging Trends of Regulation of Cancer and Apoptosis vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.1909
  4. How to Explain the Contradiction of microRNA 200c Expression and Survival in Solid Tumors?: a Meta-analysis vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3687
  5. Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling vol.32, pp.6, 2014, https://doi.org/10.3892/or.2014.3519
  6. MicroRNA-2 Suppresses Lewis Lung Cancer Cells Proliferation, Invasion, and Migration in Tumor-Bearing Mice vol.70, pp.3, 2014, https://doi.org/10.1007/s12013-014-0114-2
  7. The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis vol.10, pp.8, 2015, https://doi.org/10.1371/journal.pone.0136889
  8. The relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism and digestive cancer risk: Insights from a meta-analysis vol.16, pp.4, 2015, https://doi.org/10.1177/1470320315585908
  9. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer vol.36, pp.3, 2015, https://doi.org/10.1007/s13277-014-2760-9
  10. Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12 vol.36, pp.8, 2015, https://doi.org/10.1007/s13277-015-3340-3
  11. Critical role of miR-155/FoxO1/ROS axis in the regulation of non-small cell lung carcinomas vol.37, pp.4, 2016, https://doi.org/10.1007/s13277-015-4335-9
  12. The Expression of MicroRNA-155 in Plasma and Tissue Is Matched in Human Laryngeal Squamous Cell Carcinoma vol.57, pp.2, 2016, https://doi.org/10.3349/ymj.2016.57.2.298
  13. Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis vol.2018, pp.1875-8630, 2018, https://doi.org/10.1155/2018/8309015